Prescriber Resources
THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).
THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.
THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Enrolling in THALOMID REMS®
In order to prescribe THALOMID, you must enroll in the THALOMID REMS® program and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to the Celgene Customer Care Center at 1-888-432-9325.
Prescribing THALOMID for your patients
In order to receive THALOMID, your patients must also be enrolled in the THALOMID REMS® program. You can enroll your patients and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there.
Additionally, you can also enroll your patients by accessing the Celgene REMS mobile app for your iPad.
Learning more about THALOMID REMS®
For additional information about the THALOMID REMS® program, please see the educational materials below.
Please report adverse drug experiences that are suspected to be associated with the use of THALOMID and any suspected pregnancy occurring during the treatment with THALOMID to Celgene using any of the following methods:
REPORTING TO CELGENE |
|
Online: |
|
Email: |
|
Telephone: 1-908-673-9667 |
|
Toll-free: 1-800-640-7854 (Global Drug Safety & Risk Management) or |
|
Fax: 1-908-673-9115 |
|
Mail to: Global Drug Safety & Risk Management |
|
Other: Per individual agreement between the reporting organization and Celgene Global Drug Safety & Risk Management |
REPORTING TO THE FDA |
|
Adverse drug experiences that are suspected to be associated with the use of THALOMID and
|
|
Online: |
|
Telephone: 1-800-FDA-1088 |
|
Fax: 1-800-FDA-0178 |
|
Mail to: MedWatch |
For additional information about the THALOMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
THALOMID® and THALOMID REMS® are registered trademarks of Celgene Corporation.
© 2013-2017. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.
